Pharmaceutical companies leave no stone unturned in ensuring continuity of ongoing clinical trials, as they are
expensive, complicated, highly regulated and take years for completion. Despite the need to develop effective new
treatments, less than 5% of eligible patients participate in clinical research a situation even more pronounced for
racial and ethnic minorities. Up to 20% of clinical trials are either terminated early for failing to meet recruitment
targets or are completed while failing to meet the original target. (Noah Goodson, 2022)

The traditional clinical trial methodology was also based on the premise that patients or trial subjects need to be
present in-person at the site to ensure safety, compliance and integrity. However with the restrictions enforced
during the pandemic, sponsors had to identify alternate methods of timely and safe deliverance of medicines while
also ensuring data integrity and ensuring continuity of care.

COVID-19 pandemic tested this hypothesis as sponsors dealt with challenges not only like safely and timely
deliverance of medicines and treatments to trial subjects due to supply chain issues but also preserving the
continuity of care and ensuring data integrity